Aboudola Samer, Kini Ameet R
Department of Pathology, Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine, Maywood, Illinois 60153, USA.
Curr Opin Hematol. 2005 Jul;12(4):279-83. doi: 10.1097/01.moh.0000168521.76120.7b.
Several recent studies have focused on the role of angiogenesis in hematologic malignancies. This review specifically discusses angiogenesis in lymphoproliferative disorders, with a special emphasis on the most recent publications. The novel therapeutic strategies arising from advances in this field are reviewed, and the potential pitfalls of these therapies are also discussed.
Recent publications confirm that angiogenesis and angiogenic factors are increased in lymphoproliferative disorders. In addition, several studies have demonstrated that angiogenesis is directly involved in the pathogenesis of these disorders.
Knowledge of angiogenesis in lymphoproliferative disorders has increased substantially in the past few years. Angiogenic factors such as vascular endothelial growth factor have been shown to be important in the progression or maintenance of lymphoproliferative disorders. Targeting of these factors is therefore a promising new therapeutic approach. Hematopoietic angiogenesis is a nascent field, however, and its concepts are still evolving. A systematic approach to understanding and characterizing the angiogenic phenotype is required for the design of efficacious antiangiogenic therapeutic regimens.
近期的多项研究聚焦于血管生成在血液系统恶性肿瘤中的作用。本综述特别讨论了淋巴增殖性疾病中的血管生成，尤其着重于最新的出版物。对该领域进展所产生的新型治疗策略进行了综述，并讨论了这些疗法可能存在的缺陷。
近期的出版物证实，血管生成及血管生成因子在淋巴增殖性疾病中有所增加。此外，多项研究表明血管生成直接参与了这些疾病的发病机制。
在过去几年中，关于淋巴增殖性疾病中血管生成的知识有了显著增加。血管内皮生长因子等血管生成因子已被证明在淋巴增殖性疾病的进展或维持中起着重要作用。因此，针对这些因子是一种有前景的新治疗方法。然而，造血血管生成是一个新兴领域，其概念仍在不断发展。设计有效的抗血管生成治疗方案需要一种系统的方法来理解和表征血管生成表型。
